Well-funded biotech RHY kicks off CSIRO contract
The ASX-listed biotech Rhythm Biosciences (ASX:RHY) — a developer of the ColoSTATTM antibody based blood test targeting the accurate and early detection of colorectal cancer — this week released its first quarterly report.
RHY listed on the ASX on 7 December 2017.
Since then it has signed a key research contract with CSIRO to complete development of the key reagents needed for ColoSTATTM.
The company’s lead product is intended to provide the accurate and early detection of colorectal cancer, acting as either a ‘first-step’ screening test or as a step following a positive faecal immunochemical test (FIT) or colonoscopy.
Importantly, ColoSTATTM is also of particular value to those with risk factors associated with colorectal cancer. The technology also has the potential to become the new first step screening test for people, who for personal, cultural or clinical reasons, elect to not participate in the existing screening programs for colorectal cancer.
It is designed to be a simple blood test that is cost effective, minimally invasive and easily run by laboratories with minimal training or need for new infrastructure — which can simultaneously achieve greater patient participation and compliance than faecal tests.
It should be noted here that RHY is in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.
Key contract with CSIRO has commenced
Within days of listing on the ASX in December, RHY informed the market it had kicked off work under its research contract with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to develop the last key reagents required for ColoSTATTM.
This coincides with the company’s explicit objective to develop its own antibodies and target proteins which would allow RHY to control the supply, quality and cost of the key reagents required to manufacture the ColoSTATTM test kits. The reagents are a crucial factor in terms of producing test kits that are consistent and reliable.
While the company already has its own reagents for most of the ColoSTATTM targets, as specified in the CSIRO contract, researchers will develop these target reagents and assess their advantages over reagents that are already commercially available.
Delivery of the key reagents and ‘cell lines’ required for truly scalable and ongoing production is expected by RHY to come through in late November this year. Once it has those in place. The company can progress ColoSTATTM to a new production and validation phase.
$8.79M cash on hand as at 31 December
As mentioned, RHY commenced trading on the ASX on 7 December 2017.
RHY’s directors are pleased with the company’s progress since listing, with Chairman Shane Tanner stating: “We remain driven at achieving key deliverables under the company’s business plan to expedite the development and commercialisation of ColoSTAT.
“We are fully funded and remain on track to achieve such strategic objectives under the business plan.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.